conditions. 48
Introduction 49
Type I interferons (IFN-I) are key soluble antiviral molecules that are predominantly produced by 50 activated plasmacytoid dendritic cells (pDCs) 1 . Their functions reach far beyond their established role 51 during antimicrobial defense as IFN-I are also linked with regulation of immune cell differentiation, 52
survival and homeostasis as well as control of the cell cycle [2] [3] [4] . Hence, IFN-I play an important role in 53 orchestrating the natural immune response to cancer and have inhibitory functions that prevent 54 malignant cellular transformation (reviewed in Zitvogel, et al 5 ). However, their biological activities can 55 also have deleterious impacts on surrounding healthy cells. Prolonged IFN-I signaling is associated to 56 excessive inflammation and immune dysfunction 6 and high levels of IFN-I contributes to aberrant 57 immune activation and development of autoimmune diseases 7 . Furthermore, IFN-Is can also act as a 58 double-edged sword when fighting malignant invasive tumors, with the potential to deploy opposite anti-59 and pro-tumorigenic outcomes given their direct impact on tumor cells and potentially improper activity 60 on tumor infiltrating immune cells 8 . Thus, IFN-I production and signaling need to be tightly regulated to 61 achieve protective immunity during pathological conditions while avoiding harmful toxicity caused by 62 improper or prolonged IFN signaling. 63
One way to control IFN-I production involves the engagement of pDC-specific regulatory receptors 64 BDCA-2 (CD303) and ILT7 (LILRA4, CD85g). Crosslinking of either regulatory receptor efficiently 65 suppresses the production of IFN-I and other cytokines in response to toll-like receptor 7 and 9 (TLR7/9) 66 activation 9,10 . Interestingly, the natural ligand of ILT7 was found to be BST2 (bone-marrow stromal cell 67 antigen 2), a membrane-associated protein that is itself induced by IFN-I 11 . Given the IFN-I-inducible 68 nature of the ILT7 ligand, it was proposed that BST2 contributes to a negative feedback mechanism 69 controlling IFN-I overproduction by pDCs after viral infection and/or sustained inflammatory responses 11-70 5 Understanding the structural features of BST2 that are required to engage and activate ILT7 may guide 104 the development of new therapeutic options aimed at restoring pDC functionality and triggering IFN-I 105 production to induce effective antitumor or antiviral immunity. 106
Using functional assays measuring ILT7 activation by BST2 as well as biophysical studies of BST2 107 interaction with ILT7, we show that the structurally distinct N-and C-terminal regions of BST2 ectodomain 108 have discrete functions during ILT7 activation. While the unique and highly conserved C-terminal coiled-109 coil region of BST2 contains key residues required for ILT7 binding, the N-terminal and its central 110 connecting flexible region acts as a modulatory region negatively regulating ILT7 activation. Indeed, we 111 provide evidence that after the initial interaction, the coiled-coil internal flexibility is required for ILT7 112 activation suggesting a post-binding conformational rearrangement of the BST2/ILT7complex. We 113 further demonstrate that a stable BST2 homodimer is required to trigger ILT7 activation and that both 114 BST2 monomers need to have intact ILT7-binding surface for this function. Importantly, analysis of 115 somatic mutations identified in particular tumor tissues and mapping to these newly defined BST2 116 functional domains reveals that specific genetic changes in BST2 are capable of either greatly enhancing 117 ILT7-mediated suppression of IFN-I production or completely abrogating this phenotype, thus 118 underscoring the clinical relevance of our findings. 119 120
Results 121
The highly conserved coiled-coil region of BST2 is required for ILT7 activation. We previously 122 demonstrated that the BST2 ectodomain is sufficient to interact with ILT7 and activate its inhibitory 123 signaling cascade 30 . To identify the determinants in BST2 ectodomain required for ILT7 activation we 124 used two previously described co-culture assays, namely a reconstituted ILT7 reporter assay and a 125 PBMC-based assay (Fig. 1B) . The first functional assay relies on a mouse NFAT-GFP reporter cell line, 126 which also expresses human ILT7 and the mouse FcϵRIγ chain (CT550) such that levels of GFP 127 expression directly correlates with the degree of BST2-mediated ILT7 activation 10, 11 . Selected BST2 128 mutants were also tested in a PBMC-based co-culture assay, which directly measures the quantity of 129 IFN-I produced by PBMCs after TLR7 agonist stimulation following engagement and activation of the 130 ILT7 pathway in pDCs by BST2 30, 34 . Given that the extent of ILT7 activation is directly proportional to the 131 6 surface levels of BST2 expressed on co-cultured 293T targets cells 30 , expression of all BST2 mutants 132 was standardized to match that of the internal BST2 WT control (Fig. S1 ). A series of alanine substitution 133 mutants starting at amino acid position 47 and continuing through position 150 32 , where each mutant in 134 the panel incorporates four consecutive alanine residues, was used to identify determinants required for 135 ILT7 activation. HEK-293T cells expressing BST2 (WT or mutants) were co-cultured with ILT7 + NFAT-136 GFP reporter cells prior to flow cytometry analysis. The alanine scan analysis revealed two discrete 137 domains in BST2 that modulate ILT7 activation. A first region spanning residues 47 to 90 appeared to 138 act as a modulatory domain as alanine substitutions enhanced BST2-mediated ILT7 activation. In 139 contrast, a second region overlapping the BST2 coiled-coil domain from residues 91 to 147 seemed to 140 have a direct role in ILT7 activation as many alanine mutations resulted in a strong impairment of the 141 ILT7 activation phenotype (Fig. 1C-D) . 142
A surface required for ILT7 activation is defined by two spatially adjacent residues within the 143
BST2 coiled-coil. We confirmed that the BST2 coiled-coil region was sufficient to interact with ILT7 by 144 surface plasmon resonance in vitro (KD=2.62 μM) using recombinant GST-tagged truncated BST2 145 (residues 80 to 147) and baculovirus-expressed soluble ILT7 ( Fig. 2A) . The primary structure of the 146 coiled-coils is characterized by a periodicity of seven residues or heptad repeat pattern, which are usually 147 labeled abcdefg. Heptad positions a and d (typically hydrophobic residues) form the core present at the 148 interface of the two helices, while e and g positions (typically charged residues) form inter-helical ionic 149 interactions and are all involved in dimer stabilization 35, 36 . Some of the alanine residues introduced during 150 the alanine scan could potentially disrupt the stability of the coiled-coil structure, especially those that 151 substitute amino acid residues located at the center of the α-helix (heptad positions a and d) or those 152 involved in stabilizing inter-helical bonds (heptad positions e and g; Fig. 2B -C). Furthermore, as the BST2 153 ectodomain parallel dimer is anchored to the plasma membrane at both ends, at least one of the heptad 154 positions e or g is most probably buried as it is facing the cell surface ( Fig. 2C ). We therefore reasoned 155 that only heptad positions b, c and f are more likely to be exposed for interaction with ILT7. Based on 156 these predictions, we selected potentially exposed non-alanine residues, which were part of the 7 was confirmed using the PBMC-based assay. As expected, upon engagement of BST2 WT with ILT7, 161 IFN-I production was significantly reduced in the co-culture ( Fig. 3C and S2 ). In agreement with the lack 162 of ILT7 activation observed using the ILT7 reporter assay, BST2 D129A and R136A mutants were unable 163 to significantly trigger a repression suppression of the IFN-I pathway triggered through TLR7 activation 164 ( Fig. 3C and S2) . Interestingly, the two mutated residues, D129 and R136 are located in adjacent c 165 heptad positions ( Fig. 2C ) and as such could form a potential ILT7-binding surface in the secondary 166 structure of BST2 ( Fig. 3D) . 167
BST2 coiled-coil dynamic instability is important to modulate ILT7 activation. Alanine substitutions 168
of residues 63 to 78 in the N-terminal domain of BST2 enhanced ILT7 activation by 3-to 5-fold ( Fig. 1D ). 169
This same region was previously shown to display pronounced flexibility in the context of BST2 dimers 170 and to act as the core of a putative antiparallel 4-helix bundle made by two BST2 parallel dimers under 171 reducing conditions 24, 25 . A single residue mutant in this region, L70D, was sufficient to disrupt tetramers 172 without affecting the formation of BST2 dimers under reducing condition but had only limited effects on 173 BST2 antiviral activity 24 . When tested in the ILT7 reporter assay, substitution of leucine residue at 174 position 70 for aspartic acid significantly enhanced activation ( Fig. 4A-B ). Interestingly, this mutant 175 behaved just as BST2 WT in the PBMC-based assay ( Fig. 4C ). Given the structural feature displayed 176 by this region, the L70D mutation could also have long range effects on the dynamic of the coiled-coil 177 region. Crystal structure models from Schubert and colleagues suggest that residue L70 is buried in a 178 hydrophobic core stabilizing the BST2 dimer 24 . It is therefore possible that disrupting a strong 179 hydrophobic core within the N-terminus end of the dimer by adding a charged residue would provide 180 more flexibility to the C-terminus coiled-coil domain. In order to test whether the dynamic instability of 181 the BST2 coiled-coil plays a role in ILT7 activation, we incorporated two cysteines at positions L127 182 (L127C) and V134 (V134C) predicted to be close enough in the dimer to allow formation of disulfide 183 bonds ( Fig. 4D ). As predicted, restricting the plasticity of the BST2 coiled-coil region significantly reduced 184 ILT7 activation in the ILT7 reporter assay as well as in the PBMC-based assay ( Fig. 4A -C). These results 185 highlight the importance of BST2 coiled-coil characteristic of dynamic instability for ILT7 activation and 186 suggest that the N-terminal domain might impose a structural constraint on the coiled-coil dynamic. 187 ILT7 activation requires a structurally stable BST2 dimer. Although there are three disulfide bonds 188 (C53, C63 and C91) stabilizing the BST2 dimer 24-26 , none of the three individually is required for BST2 189 8 antiviral function 21, 22 . Loss of cysteines at position 53 and 63 did not affect the ability of BST2 to activate 190 ILT7 ( Fig. 5A-B ). On the other hand, loss of cysteine residue at position 91 drastically reduced ILT7 191 activation. Indeed, any combination that included a mutation at cysteine residue 91 displayed a strong 192 defect in ILT7 activation ( Fig. 5A-B ). Of note, N-acetylglucosamine residues at position N92 are 193 postulated to be perpendicular to the C91-C91 disulfide bond 24 . Interestingly, while N-glycosylation sites 194
were not required for ILT7 activation, disrupting C91 disulfide bond in absence of glycosylation at position 195 92, restored BST2-mediated ILT7 activation to BST2 WT levels ( Fig. 5A-B ). Nevertheless, the stabilizing 196 role of the disulfide bonds was found to be required for ILT7 activation as mutation N92Q could not 197 rescue activation when the three cysteines were mutated ( Fig. 5A-B ). In agreement with the ILT7 reporter 198 cell assay, BST2 C91A mutant was unable to significantly trigger the ILT7-dependent IFN-I repression 199 pathway in PBMCs, while no significant differences were observed between BST2 WT and the 200 C91A/N92Q mutant ( Fig. 5C ). These results indicate that although the structural stability of the BST2 201 dimer conferred by the disulfide bonds is critical for BST2-mediated ILT7 activation, the disulfide bond 202 specifically formed through Cys 91 might also contribute to the proper orientation of a neighboring highly 203 glycosylated site that otherwise could impair BST2-ILT7 engagement. 204
Given that a stable BST2 dimer is required to activate ILT7 and that the ILT7 coreceptor, FcϵRIγ, requires 205 dimerization for proper activation 37 , we investigated whether ILT7 activation requires the engagement of 206 two functionally active units within the BST2 dimer. Using a double inverse gradient of expression of 207 BST2 WT versus the R136A null mutant, we determined that only homodimers of BST2 WT are capable 208 of activating ILT7 while heterodimers between BST2 WT and the R136A mutant are inactive ( Fig. 6 A-209 B, S3A). To support these findings, we demonstrated by co-immunoprecipitation assay that BST2 WT 210 was capable of forming dimers with BST2 mutant R136A as efficiently as with BST2 WT (Fig. S3B) . 211
These findings indicate that two functionally active units of BST2 forming a stable dimer are required to 212 activate ILT7. 213
Natural variants of BST2 exhibit distinct ILT7 activation phenotypes. To examine if the BST2 214
functional domains identified so far can be affected in vivo, several natural variants of BST2 were 215 analyzed, including single nucleotide polymorphisms (SNP) and somatic mutations associated to specific 216 cancers ( Fig. 7A , Table S1 ). Most of the SNP tested were comparable to BST2 WT for ILT7 activation; 217 however, three SNPs, namely D103N, E117A and D129E, the latter revealing a substitution at the critical 218 9 D129 residue for a conserved charged amino acid, exhibited a partially impaired ILT7 activation 219 phenotype (Fig. 7B ). Likewise, three of the somatic mutations tested (E62G-hepatocellular carcinoma, 220 Q110H-ovarian cancer and S145R-lung cancer) activated ILT7 to the same extent as BST2 WT. 221
Interestingly, one somatic mutation (E119K-melanoma) located in the coiled-coil domain was completely 222 defective while three somatic mutations identified in distinct cancer tissues (C63Y-uterine cancer, Q87H-223 colon cancer and T90P-breast cancer) and mapping outside of the coiled-coil structure exhibited 224 enhanced activation capacities (Fig. 7B ). In agreement with the ILT7 reporter assay, mutation E119K 225 was completed defective in the PBMC assay ( Fig. 7C ). Based on its heptad g position ( Fig. 2C) , it is 226 predicted that the charge alteration at this position would have a very detrimental effect on the overall 227 coiled-coil stability, further highlighting the importance of the integrity of this structure for ILT7 activation. 228
However, in contrast to the BST2 C63Y and T90P mutants that behaved just as WT in this assay, BST2 229 Q87H strongly repressed IFN-I production ( Fig. 7B -C). Taken together these results suggest that variants 230 of BST2 with opposed potential to activate ILT7 can be found in vivo and be selected under pathological 231 malignant conditions. 232
Post-binding events associated to BST2 coiled-coil plasticity are required to activate ILT7. To 233 further understand the molecular mechanism underlying ILT7 activation by BST2, we analyzed the 234 binding strength of selected BST2 mutants to ILT7 using microscale thermophoresis (MST). The 235 recorded binding strength of BST2 WT ectodomain to ILT7 ectodomain by MST ( Fig. 8 and Fig. S4 , 236
KD=2.45 ± 0.3 μM) was remarkably similar to that we previously reported using surface plasmon 237 resonance (SPR) (KD=2.33 μM 30 ). Mutations in the postulated ILT7-binding surface, BST2 D129A and 238 R136A, that failed to activate ILT7 in the reporter assay and in the PBMC-based assay exhibited no 239 binding to ILT7 by MST, validating these residues as critical for ILT7 binding ( Fig. 8A and Fig. S4A ). 240
Interestingly, mutation L127C, which prevented BST2 activation of ILT7 in both functional assays by 241 presumably limiting the plasticity of the coiled-coil, interacted with ILT7 with comparable strength than 242 BST2 WT ( Fig. 8B and Fig. S4B , KD=6.45 ± 1.2 μM), implying that binding to ILT7 is required but not 243 sufficient to induce activation of the inhibitory receptor. MST analysis of BST2 mutants that enhanced 244 ILT7 activation in the reporter assay (L70D, T90P and Q87H) and in the PBMC assay (Q87H) revealed 245 that none of these mutants displayed enhanced binding affinities. Indeed, these three mutants had KD 246 values in the lower micromolar range as BST2 WT, although with different thermophoresis ( Fig. 8C -D 247 and Fig. S4C -D, Q87H KD=5.06 ± 1.1 μM; L70D KD=5.55 ± 1 μM; T90P KD=4.49 ± 0.9 μM). Whereas 248 BST2 WT and the BST2 Q87H mutant displayed a difference in amplitude when in complex with ILT7, 249 BST2 mutants L70D and T90P showed a difference in signal direction. Chemical cross-linking of 250 constructs comprising the recombinant ectodomain revealed that all mutants tested still dimerized as 251 indicated by the appearance of new bands migrating at molecular weights between 25 and 35 kDa ( Fig.  252 S4E), as previously reported 26 . To analyze the impact of the mutations on the folding and stability of the 253 proteins, we examined the circular dichroism (CD) profiles of selected BST2 mutants and determined 254 their thermostability (melting temperature, Tm). CD analyses revealed that all mutants are highly α-255 helical in solution, with a propensity to form alpha helices either very similar to BST2 WT (Q87H, L127C) 256 or just slightly reduced (70-90% helical content remaining for D129A, R136A, L70D and T90P; Fig. S5 , 257 left panels). Analysis of the thermostability showed that while most mutants (D129A, L70D, Q87H and 258 T90P) displayed melting temperature similar to BST2 WT (~61 °C), mutants harboring substitutions at 259 residues L127 or R136 in the coiled-coil domain exhibited a reduced thermostability with Tm values of 260 ~53 °C and ~54 °C, respectively ( The interaction of the human pDC receptor ILT7 with its ligand, BST2, has important biological 268 implications as it significantly regulates pDC's TLR-induced innate immune responses during 269 inflammatory injuries, a function that can be diverted in disease states 11,30,38 . However, the structural 270 determinants and functional features of BST2 that govern ILT7 engagement and activation are still 271 largely undefined. Our mutagenic studies of the BST2 ectodomain combined with biophysical analysis 272 of recombinant mutant molecules identify two structurally distinct regions of the BST2 ectodomain that 273 play divergent role during activation of ILT7. While the coiled-coil region of BST2 is found to contain 274 amino acid residues required for binding ILT7, the flexible N-terminal region of the ectodomain appears 275 to act as a negative modulator of BST2-mediated ILT7 activation. Through analysis of specific mutants, 276
we further demonstrate that binding of BST2 to ILT7 is not sufficient for activation of the receptor and 277 provide evidence that post-binding structural rearrangements involving the coiled-coil structure are likely 278 required to optimally trigger ILT7 signaling. Importantly, our results highlight the biological relevance of 279 these newly defined domain of BST2 by establishing that mutations with opposed potential to activate 280 ILT7 can be found in vivo and be selected under pathological malignant conditions. 281
The human BST2 coiled-coil is characterized by an inherent dynamic instability, which has been 282 proposed to provide structural plasticity during dynamic events such as viral assembly and release [24] [25] [26] [27] . 283
Indeed, the integrity of the coiled-coil structure rather than its amino-acid sequence composition was 284 found critical for optimal BST2 antiviral activity 22,32,33 . However, the presence of large patches of amino 285 acid sequence conservation between human BST2 and its counterparts encoded by other primates 286 suggest that the structure could also be important for a conserved cellular function involving a cell surface 287 binding partner 27 . A role of the BST2 coiled-coil as a binding interface for the ILT7 receptor is indeed 288 supported by our in vitro binding studies revealing that this structure is sufficient for binding ILT7 as well 289 as by our alanine scan mutagenesis, which clearly demonstrate that mutations encompassing the coiled-290 coil drastically affect ILT7 activation. Targeted mutagenesis of amino-acid residues predicted to be 291 exposed within the coiled-coil heptad repeats identify well conserved residues D129 and R136 as 292 essential on their own for binding ILT7 and as expected inducing its activation. In the case of the aspartic 293 acid residue at position 129, substitution for a similarly charged glutamic acid, was found still detrimental 294 for ILT7 activation, pointing to a critical role of an aspartic residue at that position. The fact that the overall 295 integrity of the coiled-coil appears minimally affected in both mutant, as shown by our biophysical 296 analyses, and that they retain the ability to form dimers, suggests that these exposed residues in 297 adjacent c positions might represent an ILT7-binding surface in BST2 although we cannot exclude the 298 possibility that ILT7 contacts BST2 at two distinct sites. Interestingly, the requirement of two, rather than 299 one, binding contacts was previously reported for ILT2 (also known as LIR-1 or LILRB1), another 300 member of the ILT family, which binds HLA-A2 39 . 301
Previous structural and functional studies have highlighted the critical role of disulfide linkages in 302 stabilizing the BST2 dimer as well as the necessity for disulfide cross-linking through at least one of the 303 three conserved cysteines for BST2 antiviral activity 21,22,24-27 . Our results demonstrate that the stabilizing 304 role of disulfide bonds is required for ILT7 activation. They also reveal an essential role of cysteine 91 305 as disulfide cross-linking at this position is predicted to prevent the detrimental effect of a neighboring 306 asparagine residue on the BST2-mediated ILT7 activation. Interestingly, none of the other two cysteines, 307 C53 and C63, were found to individually impact ILT7 activation, indicating that disulfide cross-linking at 308 C91 might serve two functions: first, ensuring the proper structural orientation of the C-terminus of the 309 ectodomain, and, second stabilizing the labile coiled-coil during dynamic processes of disassembly and 310 reassembly, which confer a degree of conformational flexibility/plasticity to the molecule 23 . Restricting 311 the dynamic process of the BST2 coiled-coil with engineered disulfide bonds predicted to be formed at 312 positions 127 and 134 drastically impaired ILT7 activation without however impairing binding of BST2 to 313 the receptor (at least with L127C). These results suggest that while binding of BST2 to ILT7 is required 314 for induction of ILT7 signaling, it might not be sufficient. This phenotype raises the possibility that post-315 binding events associated to the plasticity of the BST2 coiled-coil might be required for ILT7 activation, 316
although we cannot entirely exclude that the lack of ILT7 activation might result from the slightly reduced 317 thermostability of the L127C mutant. 318
Alanine scan and targeted mutagenesis of the N-terminal domain of BST2 at amino acid residues 63, 70 319 87 and 90 leads to an enhancement of ILT7 activation in the reporter assay without any major changes 320 in the strength of binding to ILT7 (at least for the L70D, Q87H and T90P mutants). These results suggest 321 that this region of BST2 might exert a structural constraint on the ectodomain of the molecule. They also 322 support the notion that besides binding, other molecular events might qualitatively impact BST2-323 mediated ILT7 activation. Structural studies of BST2 reveal that the N-terminal domain of BST2 forms 324 a continuous helix with the coiled-coil with and inherent constrained flexibility at a connecting hinge 325 region, which is revealed as a bent structure by small angle X-ray scattering analysis 26, 27 . However, the 326 presence of both membrane anchors might constrain the ectodomain into one defined conformation. 327
Thus, disrupting a strong hydrophobic core close to the N-terminus end of the dimer (L70D mutation) 328 could provide more flexibility to the C-terminus coiled-coil portion by reducing the backbone torsion 329 downstream. Similarly, introducing a sharp helix break with a proline before the start of the coiled-coil 330 region (T90P mutation), physically disconnecting the two domains, might relieve this structural constrain 331 and favor ILT7 activation. 332
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On the basis of our analysis of the structure-function relationship of BST2 and the current literature, we 333 propose the following model of BST2-mediated activation of the ILT7 pDC receptor. Two functionally 334 active units of BST2 forming a stable dimer are required to activate ILT7. Upon binding of each BST2 335 molecules to a single monomeric ILT7/FcϵRIγ pair at either side of the dimeric coiled-coil, the two 336 ILT7/FcϵRIγ pairs are brought close enough to induce their dimerization, a process that is facilitated by 337 the conformational flexibility of the coiled-coil structure. Once close enough, a potential disulfide bond 338 formation linking the two FcϵRIγ co-receptors would stabilize the entire complex as observed for the Fc 339 receptor complex 37 . In this context, mutations D129A or R136A would prevent the initial binding while absence of viral antagonist 40,41 . Yet, despite HIV-1 counteractions, which result in a reduction of surface 362 BST2 and efficient viral particle release, BST2 is still incorporated into virions. 22,42 These observations 363 provide indirect evidence that conditions not favoring the formation of high order associations render 364 BST2 ineffective at restricting HIV-1 release. 365
The biological importance of ILT7 activation by BST2 has been difficult to study in vivo since this function 366
is not conserved between human and mice, as there is no known murine ortholog for ILT7 14 Antibodies and reagents. Rabbit polyclonal anti-BST2 serum was previously described (Dube, 2010) . (Invitrogen) and cloned in the pcDNA3.1 backbone. All mutations introduced in BST2 were generated by 411 PCR-based mutagenesis using specific primers (Table S2 ). All mutations were validated by automated Two days prior to co-culture, HEK-293T cells were transfected with empty pcDNA3.1 or plasmids 438 encoding for BST2 WT or mutants. PBMCs at a ratio of 3:1 (PBMC:293T cell) were added in a final 439 volume of 250μl. After 4 h of co-culture, TLR7 agonist Gardiquimod was added to a final concentration 440 of 2.5 μg/ml and cells were kept in co-culture for an additional 18-24 h as previously described 30 . In all 441 conditions, co-cultures were then transferred to a V-bottom 96-well plate and centrifuged for 5 min at 442 400g. As a control, transfected HEK-293T cells were treated with TLR7 agonist in absence of PBMCs. 443
Supernatants were then used to quantify the amounts of bioactive IFN-I produced. Each experimental 444 replicate (n) was performed using cells from a different donor. 445
Quantification of IFN-I. Detection of bioactive human IFN-I was performed using reporter cell line HEK-446
Blue IFN-α/β (InvivoGen) as previously described 12 . IFN-I concentration (U/ml) was extrapolated from 447 the linear range of a standard curve generated using known amounts of IFN-I. 
BST2 dimerization assay. A converging (or double) gradient of expression was generated by 476
transfecting different ratios of plasmids encoding HA-BST2 WT and Myc BST2 136A mutants such that 477 condition 1 and 11 represent only HA-BST2 WT or Myc-BST2 R136A, respectively. and condition 6 is 478 the mid-point where each plasmid was transfected at equal ratios (50% of each). For each condition, 1.2 479 μg of total DNA was transfected. The ratio of each expression plasmid varied by 10% between each 480 condition such that as the HA-BST2 WT-expressing plasmid was reduced, the Myc-BST2 R136A-481 expressing plasmid was increased. Forty-eight hours post transfection, a replica well was used for co-482 culture with ILT7 + NFAT-GFP reporter cells to measure ILT7 activation as described above. In parallel, 483 another replica well was used for surface BST2 staining using either anti-HA, anti-Myc or anti-BST2 484 antibodies followed by flow cytometry analysis. Staining for total BST2 was used as an internal control 485 to ensure that similar levels of total surface BST2 were achieved in for all transfection conditions 486
Co-immnuoprecipitation and Western blot. HA-CAML-or HA-BST2 WT-expressing plasmids were 487 cotransfected with Myc-tagged BST2 (WT or R136A mutant) expressors in HEK-293T. Cells were 488 harvested and lysed in RIPA-DOC buffer (10 mM Tris pH 7.2, 140 mM NaCl, 8 mM Na2HPO4, 2 mM 489 NaH2PO4, 1% Nonidet-P40, 0.5% sodium dodecyl sulfate, 1.2 mM deoxycholate) 48 h post-transfection. 490
Ten percent of each lysates was preserved to control for protein expression (input). The remaining cell 491 lysates were incubated with anti-HA for 2 h at 4°C, prior to precipitation with Protein A Sepharose beads 492 (GE Healthcare). Immunoprecipitates were separated by 12.5% SDS-PAGE and analyzed for the 493 presence HA-BST2 WT or Myc-BST2 (WT or R136A mutant) or the negative control HA-CAML by 494 western blot using either anti-HA or anti-Myc Abs. 
Biophysical characterization of BST2 by circular dichroism (CD). CD spectroscopy measurements 524
were performed using a JASCO spectropolarimeter equipped with a thermoelectric temperature 525 controller. Spectra of each sample were recorded at 20 °C in buffer A (50 mM phosphate pH 7.5). For 526 thermal denaturation experiments, the ellipticity was recorded at 222 nm with 1 °C steps from 20 to 92 °C 527 with a slope of 1°/min. Ellipticity values were converted to mean residue ellipticity. 528 20 Crosslinking. BST2 WT and mutants were crosslinked with 5mM EGS (ethylene glycol bis 529 succinimidylsuccinate, Pierce) at 1mg/ml in a buffer containing 50 mM phosphate pH 7.5 for 15 min at 530 room temperature. Crossed linked samples were separated on a 15% SDS-PAGE and stained with 531
Coomassie Brilliant Blue. 532 Statistical analysis. Statistical analysis was performed using repeated measures ANOVA, with 533
Bonferroni's multiple comparison test or two-tailed paired Student's t-tests. A p value of <0.05 was 534 considered significant. The following symbols were used throughout the manuscript: *** p<0.001, ** 535 p<0.01, * p<0.05, ns not significant (p>0.05). 536 537 LUAD-YINHD G/T S145R Lung adenocarcinoma (0.11) COSM349518
TCGA-51-6867-01 G/T S145R Lung squamous cell carcinoma (0.27) † T90P was also proposed as a potential rare SNP Note: allele frequency of somatic mutations in an individual measures proportions of cells where the mutation reside in; could reflect both selective growth advantage and chronological sequence of the mutation (Reported by cBioportal). . b, Identification of potentially individual exposed residues within BST2 coiled-coil region. Sequence of BST2 coiled-coil region, position of alanine scan mutants that failed to activate ILT7 (in bold), coiled-coil heptad positions (denoted a-g), positions most likely to be exposed (in bold; stutter position in red) as well as individual alanine substitutions of predicted BST2 exposed residues are indicated. c, Helical wheel diagram of the homodimeric parallel coiled-coil of BST2 (residues depicted from position 91-116 and 117-147). The primary structure of each helix is characterized by a periodicity of seven residues or heptad repeat pattern. Heptad positions a and d (shaded green) are typically hydrophobic core residues present at the interface of the two helices, while e and g positions (shaded purple) typically form inter-helical ionic interactions and are all involved in the dimer formation. Residues often found in the remaining heptad repeat positions b, c, and f are exposed for potential interaction with binding partners. Charged amino acids are colored (negative in red and positive in blue). Given the BST2 unique double membrane anchored conformation, its fixed membrane facing interphase is highlighted as well. of predicted exposed BST2 residues on ILT7 activation. a, Relative BST2 surface expression in HEK-293T cells transfected with control plasmids or plasmids encoding the indicated BST2 mutants (n=6). Percentages of MFIs were calculated as in Figure 1 . b, ILT7+ NFAT-GFP reporter cells were co-cultured for 18-24 h with HEK-293T cells expressing the indicated BST2 mutants and analyzed by flow cytometry (n=6). Percentage of ILT7 activation was plotted as described in Figure 1 . Error bars represent SD. c, HEK-293T cells expressing the indicated BST2 mutants were co-cultured with freshly isolated PBMCs and levels of bioactive IFN-I released in supernatants in response to TLR7 agonist was measured 18-24 h later. Results are expressed as relative percentage of IFN-I released by PBMCs in contact with HEK-293T cells transfected with the empty plasmid in presence of TLR 7 agonist (100%, n=12). Figure 1 . b, ILT7+ NFAT-GFP reporter cells were co-cultured for 18-24 h with HEK-293T cells expressing the indicated BST2 mutants and analyzed by flow cytometry (n=6). Percentage of ILT7 activation was plotted as described in Figure 1 . Error bars represent SD. c, Control, BST2 WT or selected mutants (L70D and L127C)-expressing HEK-293T cells were co-cultured with freshly isolated PBMCs and levels of bioactive IFN-I released in supernatants in response to TLR7 agonist was measured as described in Figure 3 Figure 1 . b, ILT7+ NFAT-GFP reporter cells were co-cultured for 18-24 h with HEK-293T cells expressing the indicated BST2 mutants and analyzed by flow cytometry (n=6). Percentage of ILT7 activation was plotted as described in Figure 1 . Error bars represent SD. c, Control, BST2 WT or selected mutants-expressing HEK-293T cells were co-cultured with freshly isolated PBMCs and levels of bioactive IFN-I released in supernatants in response to TLR7 agonist was measured as described in Figure 3 A converging (or double) gradient of expression of HA-BST2 WT and Myc-BST2 R136A was generated in HEK-293T cells such that conditions 1 and 11 represent solely HA-BST2 WT or Myc-BST2 R136A, respectively whereas condition 6 is the mid-point where each isoform is predicted to be at 50%. Total amounts of transfected DNA were identical in all conditions. a, Flow cytometry analysis of surface BST2 in HEK-293T cells transfected with conditions 1 to 11 of the above-mentioned converging gradient for HA-BST2 WT (red) and Myc-BST2 R136A (blue). Ratios of each isoform for all conditions are plotted as percentage of total BST2, as calculated in the examples described in Fig. S3 . b, Relative ILT7 activation from converging BST2 gradient. ILT7+ NFAT-GFP reporter cells were co-cultured for 18-24 h with control (empty) or HEK-293T cells expressing the above-mentioned BST2 gradient for 18-24 h and analyzed by flow cytometry. Percentage of ILT7 activation was plotted as % of GFP+ cells in each condition relative to the HA-BST2 WT condition (100%) after subtracting the % of GFP+ cells in the no BST2 condition (0%). The predicted curves if only homodimers of BST2 WT or if both homodimers of BST2 WT and heterodimers between BST2 WT and R136A were capable of activating ILT7 are indicated in dark grey squares and light grey triangles respectively. plasmids or plasmids encoding the indicated BST2 mutants containing the single nucleotide polymorphisms or somatic mutations described in table S1 (n=6). All Percentages of MFIs were calculated as in Figure 1 . b, ILT7+ NFAT-GFP reporter cells were co-cultured for 18-24 h with HEK-293T cells expressing the indicated BST2 mutants and analyzed by flow cytometry (n=6). Percentage of ILT7 activation was plotted as described in Figure 1 . Error bars represent SD. c, Control, BST2 WT or selected mutants-expressing HEK-293T cells were co-cultured with freshly isolated PBMCs and levels of bioactive IFN-I released in supernatants in response to TLR7 agonist was measured as described in Figure 3 (n=9). Statistical significance was determined by applying repeated measures ANOVA with Bonferroni's multiple comparison test was used.
